Davis Polk & Wardwell advised Immatics N.V. on the offering, and Covington & Burling advised the underwriters. Immatics N.V. (Nasdaq: IMTX) announced its $201 million SEC-registered offering...
You must be a Standard 1 Year member to access this content.
Davis Polk & Wardwell advised Immatics N.V. in the deal. Immatics N.V. announced its $35 million private placement of ordinary shares. All of the shares were purchased...
You must be a Standard 1 Year member to access this content.
Davis Polk advised Immatics on the offering while Covington represented underwriters. Immatics N.V. executed its $110 million SEC-registered offering of ordinary shares. The ordinary shares are...
You must be a Standard 1 Year member to access this content.
Cooley LLP advised Immatics on the deal. Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced its license, development...
You must be a Standard 1 Year member to access this content.
